SCHEMBL7929892

SCHEMBL7929892

Fc1ccc(-c2cnc3c(Br)cccn23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.58
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
NFKB1 P19838 2/20 0.50
RAB9A P51151 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
IDO1 P14902 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880394 0.78 IDO1 (0.53) FLT3MEN1KMT2AKDM4ENPC1
SCHEMBL30566633 0.74 IDO1 (0.48) MEN1KMT2AKDM4ENPC1ALDH1A1
SCHEMBL21631035 0.74 IDO1 (0.48) MEN1KMT2AKDM4ENPC1ALDH1A1
SCHEMBL13180735 0.73 FLT3 (1.00) FLT3MEN1KMT2AKDM4ENPC1
SCHEMBL2651026 0.73 KDM4E (0.49) FLT3MEN1KMT2AKDM4ENPC1
SCHEMBL5404541 0.73 TTK (0.56) FLT3MEN1KMT2AKDM4ENPC1
SCHEMBL1873538 0.73 MEN1 (0.56) FLT3MEN1KMT2AKDM4ENPC1
SCHEMBL7941415 0.72 LMNA (0.35) FLT3MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL7936130 0.72 NPC1 (0.46) MEN1KMT2ANPC1ALDH1A1MAPT
SCHEMBL5403960 0.70 FLT3 (0.56) FLT3MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546440-B2 Substituted bicyclic imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2013-10-01 US disclosed
US-8546440-B2 Substituted bicyclic imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2013-10-01 US disclosed
US-20110237580-A1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS Janssen Pharmaceuticals, Inc. 2011-09-29 US disclosed
WO-2010070008-A1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237580-A1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 FLT3 386/4885MEN1 1785/4885KMT2A 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.